Emblem Corp EMMBF

RE:prospectus filed

[deminimis]

Where do you see that? On page on page 16 it says: 

If the Over-Allotment Option is exercised in full, as is anticipated to occur on the Closing Date, the net proceeds to the Corporation from the Offering will be approximately $50,275,001.46

Other interesting things:

The Corporation intends to use the net proceeds from the Offering as follows: Use of Proceeds (in millions) Paris Road Expansion, including the unfunded portion of the Paris Road Expansion and start-up costs $26.3M Pharmaceutical formulation development, including formulation development research and trials $3.4M The remaining net proceeds will be used for general working capital purposes. See “Working Capital” for further information. $17.1M

Working Capital:


The remaining net proceeds of the Offering will be used for general working capital purposes, which may include establishing new international distribution channels in jurisdictions where there is a federal legal framework for medical cannabis and the associated costs of compliance with applicable regulatory requirements. As the ACMPR permits licensed producers to export their intellectual property and genetics to other jurisdictions (subject to all applicable import and export permits and requirements), the Corporation is focused on developing international alliances and expansion in order to establish new international distribution channels. While the Corporation continues to evaluate potential new international distribution channels, the Corporation has not yet entered into definitive agreements in respect of any new international distributions channels. There can be no assurances that any of the new international distribution channels being evaluated by the Corporation will ultimately be pursued and, if pursued, what the timing, regulatory costs for compliance (including costs relating to obtaining the applicable import and export permits from Health Canada) and other working capital requirements may be. All of the Corporation’s current international activities are only in jurisdictions where a federal legal framework has been established for medical cannabis and such activities are in accordance with export permits issued to the Corporation by Health Canada. The Corporation will consider future international medical cannabis opportunities only to the extent that a federal legal framework develops for any such opportunities in the applicable jurisdiction.